Approved consistent with clarification in FDA memo of 8-13-02. Before its next submission, FDA shall review the information collection requirements in this regulation to evaluate whether their utility justifies their burden. FDA will report on this in its next submission.
Inventory as of this Action
Requested
Previously Approved
09/30/2005
09/30/2005
08/31/2002
4,184
0
4,184
848,625
0
848,625
0
0
0
Section 501(a)(2)(B) (21 U.S.C. 351(a)(2)(B)) of the Food, Drug, and Cosmetic Act deems a drug to be adulterated if the methods used in, or facilities or controls used for, its manufacturer, processing, packing, or holding do not conform to or are not operated or administered in conformity with CGMPs to ensure that such drug meets the requirements of the act as to safety and has the identity and strength, and meets the quality and purity characteristics, which it purports or is represented to possess.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.